The verdict
Our read at a glance.
Whether daily vasodilation produces a training or body-composition benefit beyond the approved indications.
- The signal
- The approved evidence is strong across three separate indications - erectile dysfunction, the lower urinary tract symptoms of benign prostatic hyperplasia, and pulmonary arterial hypertension - with labelled products and large trial programmes, including a daily low-dose regimen. Research has also examined its endothelial and metabolic effects, which is where the performance rationale comes from. What is missing is a demonstration that any of that translates into training adaptation, strength or body composition in healthy people; the pump is real vasodilation and has not been shown to produce a downstream benefit.
- The unknown
- Whether chronic PDE5 inhibition in healthy young men does anything useful or anything harmful over years, since the long-term data come from older men with the approved conditions.
- Our read
- A well-evidenced drug being used for something it has never been tested for. The vasodilation is real and immediately noticeable, which is exactly why people conclude it is doing more than it has been shown to do. The nitrate and stacked-vasodilator interaction is the part that actually matters.
The mechanism
How it works.
Nitric oxide released in vascular tissue activates guanylate cyclase, producing cyclic GMP, which relaxes smooth muscle and dilates vessels. Phosphodiesterase type 5 is the enzyme that degrades cyclic GMP and ends that signal. Tadalafil inhibits PDE5, so cyclic GMP persists and vasodilation is sustained - in the corpus cavernosum, which is the erectile indication, in prostatic and bladder smooth muscle, which is the BPH indication, and in pulmonary vasculature, which is the pulmonary hypertension indication. Its long half-life is what makes daily dosing practical and produces continuous rather than episodic effect. The performance rationale extends this to skeletal muscle: more blood flow means more oxygen and nutrient delivery, and the visible pump is that mechanism working. Whether sustained vasodilation improves training adaptation is a separate question, and it has not been answered.
Safety & regulatory boundary
The consequential part.
Approved for the indications above; daily use for pumps or performance is off-label. The critical interaction is with nitrates, where the combination can cause profound and dangerous hypotension, and it should be used cautiously with alpha-blockers and other vasodilators - including the citrulline and nitric-oxide precursors common in this population. Rare but serious reported events include non-arteritic anterior ischaemic optic neuropathy and sudden hearing loss. Prohibited in some sporting contexts.
What's next
What we're watching.
Any trial with training or body-composition endpoints, and long-term data in young healthy users.
Context
Why this is discussed.
It is prescribed daily at low dose legitimately, it improves the pump noticeably, and it is used to offset the sexual side effects of other compounds.
The evidence base
23 cited references.
Regulatory & labels3
A-S Medication Solutions (FDA label) · 2024
Aurobindo Pharma Limited (FDA label) · 2024
Solco Healthcare US, LLC (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · PHASE4 · NOT_YET_RECRUITING · 2026-07-30
ClinicalTrials.gov · NA · COMPLETED · 2023-06-10
ClinicalTrials.gov · PHASE3 · RECRUITING · 2022-05-04
ClinicalTrials.gov · PHASE2 · COMPLETED · 2021-03-16
ClinicalTrials.gov · NA · RECRUITING · 2026-07-01
ClinicalTrials.gov · PHASE4 · COMPLETED · registry record
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-08-01
ClinicalTrials.gov · PHASE3 · COMPLETED · 2025-01-30
Indexed literature (PubMed)12
Infante Hernández S et al. · Med Clin (Barc) · 2024
Inamura S et al. · Int J Urol · 2024
Langan RC · Prim Care · 2019
Madersbacher S et al. · Gerontology · 2019
Devlin CM et al. · BJU Int · 2021
Egan KB · Urol Clin North Am · 2016
Am Fam Physician · Am Fam Physician · 2023
Kaplan SA · J Urol · 2023
Kaplan SA · J Urol · 2023
Kaplan SA · J Urol · 2023
Bruskewitz R · J Urol · 1997
Kaplan SA · J Urol · 2023
Keep reading